Due to its tumor-specific expression, MAGE-A4 represents an ideal tumor-associated antigen for developing novel cancer immunotherapy strategies, such as peptide vaccines and TCR-T cell therapies, showing broad clinical potential. Here, MAGEA4 is linked to cancer.